Immunotherapy leverages the body’s immune system to recognize and attack cancer cells, with immune checkpoint inhibitors such as pembrolizumab and nivolumab successfully targeting proteins like PD-1 and PD-L1 to enhance the immune response against cancer cells [15,16]. The gene discussed is CD274; the disease is cancer.